基因重组生长激素在COPD急性加重期的治疗  

Use of Recombinant Human Growth Hormone for Severe Chronic Obstructive Pulmonary Disease

作　　者：李军[1] 刘立[1] 许玲华[1] 

机构地区：[1]江苏省徐州市东南大学医学院附属徐州医院,221009

出　　处：《临床肺科杂志》2004年第2期144-145,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的　研究基因重组生长激素 (r- h GH)在慢性阻塞性肺疾病 (COPD)急性加重期治疗中的临床应用价值。方法　 30例 COPD急性加重期患者随机分成生长激素组和对照组。两组均给予抗感染、氧疗及营养支持等。生长激素组在上述治疗基础上加用 r- h GH,每晚 1次皮下注射 ,连续应用 7～ 10日。观察各组的治疗疗程 ,治疗前后的血糖峰值及胰岛素的用量。结果　生长激素组平均疗程 9.9± 3.8日 ,少于对照组 (13.8± 4 .3日 ) (p<0 .0 5 ) ,两组治疗前后的血糖峰值及胰岛素用量无显著差异。结论　 r- h GH能够缩短Objective To investigate the effects of recombinant human growth hormone(r-hGH) in patients with severe chronic obstructive pulmonary disease(COPD)Methods 30 patients with COPD were randomly assigned to r-hGH group and control group.Each group patients were treated with antibiotic,oxygen therapy and allowance of nutrients.The growth hormone was injected subcutaneously to the patients of r-h GH group in every evening for 7-10 days.The treatment days,peak blood sugar content before and after treatment and insulin dosage were observed. Results The average treatment days in r-hGH group was 9.9±3.8,which was less than those in control grpups(13.8±4.3):P<0.05.There was not significant difference in peak blood sugar content and insulin dosage between the r-hGH group and the cntrol group.Conclusion The treatment days for severe COPD could be reduced by the use of recombinant human growth hormone.

关 键 词：基因重组生长激素 慢性阻塞性肺疾病 

分 类 号：R563.9[医药卫生—呼吸系统]